摘要
过敏性紫癜(HSP)是一种以全身弥漫性坏死性小血管炎为基本病理改变的炎症性疾病,儿童时期最常见,该病的发病率及复发率较高,其最主要的脏器损害及决定预后的关键在肾脏。在既往治疗中,多种免疫抑制剂如环磷酰胺、他克莫司、环孢素A、来氟米特、吗替麦考酚酯(MMF)等已用于过敏性紫癜性肾炎(HSPN),但对于其选择尚存在争议。MMF作为一种新型免疫抑制剂,其毒副作用较其他免疫制剂低,更为安全,在临床上已较为广泛地用于狼疮性肾炎、肾病综合征、紫癜性肾炎等疾病,但关于MMF治疗HSPN的研究和认识目前尚未统一标准。为此,该文就近年MMF治疗HSPN的研究进展进行综述,旨在为MMF治疗HSPN统一认识提供参考。
Henoch-Sch nlein purpura(HSP) is the most common vasculitic disease of childhood that is characterized by systemic diffuse necrotizing vasculitis with high incidence and recurrence rates.It is mainly involved in the renal impairment,which is a key factor determining prognosis.Although a variety of immunosuppressive agents,such as cyclophosphamide,tacrolimus,cyclosporine A,leflunomide and mycophenolate mofetil(MMF),have been used in the treatment of HSP nephritis(HSPN),their application remains controversial.As a new immunosuppressant,MMF has a less side effect and has been widely used in lupus nephritis,nephrotic syndrome and purpura nephritis.However,there is no uniform standard regarding the treatment of HSPN with MMF at present.This paper reviews the research progress in MMF for HSPN and provides a reference for the unified understanding of HSPN treatment with MMF.
作者
廖建英
吴冬科
LIAO Jian-ying;WU Dong-ke(2015 Grade of Medical Department of Graduated School,Nanchang University,Nanchang 330006,China;Department of Pediatrics,the First Affiliated Hospital,Nanchang University,Nanchang 330006,China)
出处
《实用临床医学（江西）》
CAS
2019年第1期96-99,共4页
Practical Clinical Medicine
关键词
过敏性紫癜性肾炎
免疫抑制剂
吗替麦考酚酯
儿童
Henoch-Sch nlein purpura nephritis
immunosuppressive agents
mycophenolate mofetil
children
